{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T10:00:43Z","timestamp":1772618443461,"version":"3.50.1"},"reference-count":96,"publisher":"Georg Thieme Verlag KG","issue":"05","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Semin Neurol"],"published-print":{"date-parts":[[2022,10]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Migraine, a primary headache disorder is a chronic and complex neurological disease that affects millions of people worldwide, impacting their quality of life. It is one of the most common reasons why individuals seek the advice of their physician, and is one of the most common referrals seen in the offices of general neurologists and headache specialists. In the past decade, there has been robust research on not only the pathophysiology of migraine but in the efforts to treat and, importantly, prevent. The introduction of calcitonin gene related peptide antagonists (CGRP-A) have opened new doors for preventive treatment options. OnabotulinumtoxinA (BoNTA) has remained a staple in the treatment of chronic migraine with data emerging with combination therapy. Neurostimulation has offered additional nonpharmacologic approaches to migraine treatment. In addition to lifestyle and behavioral modifications, these have changed the landscape of migraine prevention.<\/jats:p>","DOI":"10.1055\/s-0042-1758781","type":"journal-article","created":{"date-parts":[[2022,12,14]],"date-time":"2022-12-14T05:46:17Z","timestamp":1670996777000},"page":"558-570","source":"Crossref","is-referenced-by-count":2,"title":["Prevention of Migraine"],"prefix":"10.1055","volume":"42","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2124-9326","authenticated-orcid":false,"given":"Ashley","family":"Holdridge","sequence":"additional","affiliation":[{"name":"Department of Neurology and Headache, Advocate Aurora HealthCare, Whitefish Bay, Wisconsin"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer","family":"Buczyner","sequence":"additional","affiliation":[{"name":"Department of Neurology, First Choice Neurology, Palm Beach Gardens, Florida"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cristina Cabret","family":"Aymat","sequence":"additional","affiliation":[{"name":"Department of Neurology and Headache, Ochsner Health Center \u2013 Covington, Covington, Louisiana"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ariel","family":"Le","sequence":"additional","affiliation":[{"name":"Department of Neurology, First Choice Neurology, Palm Beach Gardens, Florida"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"194","published-online":{"date-parts":[[2022,12,13]]},"reference":[{"issue":"01","key":"ref1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/0333102417738202","article-title":"Headache Classification Committee of the International Headache Society (IHS). The International Classification of Headache Disorders, 3rd edition","volume":"38","year":"2018","journal-title":"Cephalalgia"},{"issue":"05","key":"ref2","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1016\/j.mayocp.2016.02.013","article-title":"Impact of migraine on the family: perspectives of people with migraine and their spouse\/domestic partner in the CaMEO Study","volume":"91","author":"D C Buse","year":"2016","journal-title":"Mayo Clin Proc"},{"issue":"01","key":"ref3","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1111\/head.14024","article-title":"The prevalence and impact of migraine and severe headache in the United States: updated age, sex, and socioeconomic-specific estimates from government health surveys","volume":"61","author":"R Burch","year":"2021","journal-title":"Headache"},{"issue":"05","key":"ref4","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1111\/head.13275","article-title":"Direct and indirect healthcare resource utilization and costs among migraine patients in the United States","volume":"58","author":"M Bonafede","year":"2018","journal-title":"Headache"},{"issue":"03","key":"ref5","first-page":"586","article-title":"Pathophysiology of migraine","volume":"27","author":"A Recober","year":"2021","journal-title":"Continuum (Minneap Minn)"},{"issue":"12","key":"ref6","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1038\/s41582-018-0098-4","article-title":"Biological insights from the premonitory symptoms of migraine","volume":"14","author":"N Karsan","year":"2018","journal-title":"Nat Rev Neurol"},{"issue":"09","key":"ref7","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1177\/0333102415613612","article-title":"Variability of the characteristics of a migraine attack within patients","volume":"36","author":"M Viana","year":"2016","journal-title":"Cephalalgia"},{"issue":"01","key":"ref8","first-page":"17","article-title":"Migraine headache prophylaxis","volume":"99","author":"H Ha","year":"2019","journal-title":"Am Fam Physician"},{"issue":"05","key":"ref9","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1212\/01.wnl.0000252808.97649.21","article-title":"Migraine prevalence, disease burden, and the need for preventive therapy","volume":"68","author":"R B Lipton","year":"2007","journal-title":"Neurology"},{"issue":"07","key":"ref10","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1046\/j.1468-2982.2002.00386.x","article-title":"Migraine: preventive treatment","volume":"22","author":"S D Silberstein","year":"2002","journal-title":"Cephalalgia"},{"issue":"06","key":"ref11","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1177\/0333102414547138","article-title":"Adherence to oral migraine-preventive medications among patients with chronic migraine","volume":"35","author":"Z Hepp","year":"2015","journal-title":"Cephalalgia"},{"key":"ref12","first-page":"973","article-title":"Preventive migraine treatment","volume":"21","author":"S D Silberstein","year":"2015","journal-title":"Continuum (Minneap Minn)"},{"issue":"17","key":"ref13","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1212\/WNL.0b013e3182535d20","article-title":"Evidence-based guideline update: pharmacologic treatment for episodic migraine prevention in adults: report of the Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society","volume":"78","author":"S D Silberstein","year":"2012","journal-title":"Neurology"},{"issue":"08","key":"ref14","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1111\/j.1526-4610.2008.01217.x","article-title":"Acute migraine medications and evolution from episodic to chronic migraine: a longitudinal population-based study","volume":"48","author":"M E Bigal","year":"2008","journal-title":"Headache"},{"issue":"03","key":"ref15","first-page":"613","article-title":"Preventive migraine treatment","volume":"27","author":"R Burch","year":"2021","journal-title":"Continuum (Minneap Minn)"},{"issue":"05","key":"ref16","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1111\/j.1526-4610.2004.04089.x","article-title":"Tools for diagnosing migraine and measuring its severity","volume":"44","author":"R B Lipton","year":"2004","journal-title":"Headache"},{"issue":"01","key":"ref17","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/S0304-3959(00)00305-5","article-title":"Validity of the Migraine Disability Assessment (MIDAS) score in comparison to a diary-based measure in a population sample of migraine sufferers","volume":"88","author":"W F Stewart","year":"2000","journal-title":"Pain"},{"issue":"05","key":"ref18","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1212\/WNL.44.5.837","article-title":"The Henry Ford Hospital Headache Disability Inventory (HDI)","volume":"44","author":"G P Jacobson","year":"1994","journal-title":"Neurology"},{"issue":"01","key":"ref19","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1111\/head.13701","article-title":"Content validity of HIT-6 as a measure of headache impact in people with migraine: a narrative review","volume":"60","author":"C R Houts","year":"2020","journal-title":"Headache"},{"issue":"07","key":"ref20","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1177\/0333102414552532","article-title":"The impact of chronic migraine: the Chronic Migraine Epidemiology and Outcomes (CaMEO) Study methods and baseline results","volume":"35","author":"A M Adams","year":"2015","journal-title":"Cephalalgia"},{"issue":"09","key":"ref21","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1111\/head.13157","article-title":"Migraine prophylaxis and acute treatment patterns among commercially insured patients in the United States","volume":"57","author":"J M Woolley","year":"2017","journal-title":"Headache"},{"issue":"01","key":"ref22","doi-asserted-by":"crossref","first-page":"22","DOI":"10.18553\/jmcp.2014.20.1.22","article-title":"Systematic review of migraine prophylaxis adherence and persistence","volume":"20","author":"Z Hepp","year":"2014","journal-title":"J Manag Care Pharm"},{"issue":"04","key":"ref23","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1111\/head.12055","article-title":"Patterns of use and reasons for discontinuation of prophylactic medications for episodic migraine and chronic migraine: results from the second international burden of migraine study (IBMS-II)","volume":"53","author":"A M Blumenfeld","year":"2013","journal-title":"Headache"},{"issue":"06","key":"ref24","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1136\/jnnp.2007.134023","article-title":"Migraine prevention","volume":"7","author":"D W Dodick","year":"2007","journal-title":"Pract Neurol"},{"issue":"11","key":"ref25","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1212\/WNL.58.11.1652","article-title":"A randomized trial of divalproex sodium extended-release tablets in migraine prophylaxis","volume":"58","author":"F G Freitag","year":"2002","journal-title":"Neurology"},{"issue":"02","key":"ref26","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1046\/j.1468-2982.1997.1702103.x","article-title":"Divalproex sodium in migraine prophylaxis: a dose-controlled study","volume":"17","author":"J Klapper","year":"1997","journal-title":"Cephalalgia"},{"issue":"06","key":"ref27","first-page":"CD010610","article-title":"Topiramate for the prophylaxis of episodic migraine in adults","author":"M Linde","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"issue":"10","key":"ref28","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1007\/s11916-015-0521-0","article-title":"A narrative review of evidence-based preventive options for chronic migraine","volume":"19","author":"A J Starling","year":"2015","journal-title":"Curr Pain Headache Rep"},{"issue":"01","key":"ref29","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1111\/head.12997","article-title":"Topiramate in migraine prevention: a 2016 perspective","volume":"57","author":"S D Silberstein","year":"2017","journal-title":"Headache"},{"issue":"01","key":"ref30","doi-asserted-by":"crossref","first-page":"22","DOI":"10.2174\/1573402114666180918102735","article-title":"Three generations of \u03b2-blockers: history, class differences and clinical applicability","volume":"15","author":"G T do Vale","year":"2019","journal-title":"Curr Hypertens Rev"},{"issue":"03","key":"ref31","doi-asserted-by":"crossref","first-page":"e0212785","DOI":"10.1371\/journal.pone.0212785","article-title":"Beta-blockers for the prevention of headache in adults, a systematic review and meta-analysis","volume":"14","author":"J L Jackson","year":"2019","journal-title":"PLoS One"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1136\/bmj.322.7277.19","article-title":"Prophylactic treatment of migraine with angiotensin converting enzyme inhibitor (lisinopril): randomised, placebo controlled, crossover study","volume":"322","author":"H Schrader","year":"2001","journal-title":"BMJ"},{"issue":"01","key":"ref33","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1001\/jama.289.1.65","article-title":"Prophylactic treatment of migraine with an angiotensin II receptor blocker: a randomized controlled trial","volume":"289","author":"E Tronvik","year":"2003","journal-title":"JAMA"},{"issue":"S 01","key":"ref34","doi-asserted-by":"crossref","first-page":"S61","DOI":"10.1007\/s10072-009-0071-5","article-title":"Migraine and psychiatric disorders: comorbidities, mechanisms, and clinical applications","volume":"30","author":"S M Baskin","year":"2009","journal-title":"Neurol Sci"},{"issue":"22","key":"ref35","doi-asserted-by":"crossref","first-page":"e6989","DOI":"10.1097\/MD.0000000000006989","article-title":"Tricyclic antidepressants for preventing migraine in adults","volume":"96","author":"X M Xu","year":"2017","journal-title":"Medicine (Baltimore)"},{"issue":"04","key":"ref36","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1007\/s11940-019-0557-2","article-title":"Antidepressants for preventive treatment of migraine","volume":"21","author":"R Burch","year":"2019","journal-title":"Curr Treat Options Neurol"},{"issue":"02","key":"ref37","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1111\/j.1526-4610.2005.05029.x","article-title":"The efficacy and safety of venlafaxine in the prophylaxis of migraine","volume":"45","author":"S N Ozyalcin","year":"2005","journal-title":"Headache"},{"issue":"04","key":"ref38","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1159\/000491524","article-title":"Withdrawal symptoms after serotonin-noradrenaline reuptake inhibitor discontinuation: systematic review","volume":"87","author":"G A Fava","year":"2018","journal-title":"Psychother Psychosom"},{"issue":"09","key":"ref39","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.4088\/JCP.v69n0912","article-title":"An 8-week, open-label trial of duloxetine for comorbid major depressive disorder and chronic headache","volume":"69","author":"F M Volpe","year":"2008","journal-title":"J Clin Psychiatry"},{"issue":"05","key":"ref40","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1001\/jamaneurol.2017.5144","article-title":"Association of coprescription of triptan antimigraine drugs and selective serotonin reuptake inhibitor or selective norepinephrine reuptake inhibitor antidepressants with serotonin syndrome","volume":"75","author":"Y Orlova","year":"2018","journal-title":"JAMA Neurol"},{"issue":"04","key":"ref41","first-page":"533","article-title":"Serotonin syndrome","volume":"13","author":"J Volpi-Abadie","year":"2013","journal-title":"Ochsner J"},{"issue":"01","key":"ref42","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/s10194-015-0503-y","article-title":"Burden of migraine related to menses: results from the AMPP study","volume":"16","author":"J M Pavlovi\u0107","year":"2015","journal-title":"J Headache Pain"},{"issue":"02","key":"ref43","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1212\/01.WNL.0000134620.30129.D6","article-title":"A randomized trial of frovatriptan for the intermittent prevention of menstrual migraine","volume":"63","author":"S D Silberstein","year":"2004","journal-title":"Neurology"},{"issue":"14","key":"ref44","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1517\/14656566.2014.947959","article-title":"Menstrual migraine: an updated review on hormonal causes, prophylaxis and treatment","volume":"15","author":"S Silberstein","year":"2014","journal-title":"Expert Opin Pharmacother"},{"issue":"07","key":"ref45","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1111\/head.13849","article-title":"Mechanism of action of OnabotulinumtoxinA in chronic migraine: a narrative review","volume":"60","author":"R Burstein","year":"2020","journal-title":"Headache"},{"issue":"06","key":"ref46","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1111\/j.1526-4610.2010.01678.x","article-title":"OnabotulinumtoxinA for treatment of chronic migraine: pooled results from the double-blind, randomized, placebo-controlled phases of the PREEMPT clinical program","volume":"50","author":"D W Dodick","year":"2010","journal-title":"Headache"},{"issue":"07","key":"ref47","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1177\/0333102410364676","article-title":"OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 1 trial","volume":"30","author":"S K Aurora","year":"2010","journal-title":"Cephalalgia"},{"issue":"05","key":"ref48","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1111\/head.13074","article-title":"Insights into the functional anatomy behind the PREEMPT injection paradigm: guidance on achieving optimal outcomes","volume":"57","author":"A M Blumenfeld","year":"2017","journal-title":"Headache"},{"issue":"06","key":"ref50","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1111\/head.13510","article-title":"Calcitonin gene-related peptide modulators - the history and renaissance of a new migraine drug class","volume":"59","author":"R Hargreaves","year":"2019","journal-title":"Headache"},{"issue":"02","key":"ref51","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1080\/14728222.2020.1724285","article-title":"Calcitonin gene-related peptide (CGRP): role in migraine pathophysiology and therapeutic targeting","volume":"24","author":"A S Wattiez","year":"2020","journal-title":"Expert Opin Ther Targets"},{"issue":"23","key":"ref52","doi-asserted-by":"crossref","first-page":"4588","DOI":"10.1111\/bph.15657","article-title":"Pharmacological treatment of migraine: drug classes, mechanisms of action, clinical trials and new treatments","volume":"178","author":"F Zobdeh","year":"2021","journal-title":"Br J Pharmacol"},{"issue":"02","key":"ref53","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1002\/ana.410280213","article-title":"Vasoactive peptide release in the extracerebral circulation of humans during migraine headache","volume":"28","author":"P J Goadsby","year":"1990","journal-title":"Ann Neurol"},{"issue":"01","key":"ref54","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1002\/ana.410330109","article-title":"The trigeminovascular system and migraine: studies characterizing cerebrovascular and neuropeptide changes seen in humans and cats","volume":"33","author":"P J Goadsby","year":"1993","journal-title":"Ann Neurol"},{"issue":"01","key":"ref55","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1046\/j.1468-2982.2002.00310.x","article-title":"CGRP may play a causative role in migraine","volume":"22","author":"L H Lassen","year":"2002","journal-title":"Cephalalgia"},{"issue":"10","key":"ref56","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1177\/0333102419844711","article-title":"Peripheral and central nervous system distribution of the CGRP neutralizing antibody [125I] galcanezumab in male rats","volume":"39","author":"K W Johnson","year":"2019","journal-title":"Cephalalgia"},{"key":"ref57","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1016\/S0140-6736(19)32504-8","article-title":"Targeting calcitonin gene-related peptide: a new era in migraine therapy","volume":"394","author":"A Charles","year":"2019","journal-title":"Lancet"},{"issue":"07","key":"ref58","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1111\/head.14153","article-title":"The American Headache Society Consensus Statement: update on integrating new migraine treatments into clinical practice","volume":"61","author":"J Ailani","year":"2021","journal-title":"Headache"},{"issue":"13","key":"ref59","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1177\/0333102420946725","article-title":"Real-world effectiveness and tolerability of erenumab: a retrospective cohort study","volume":"40","author":"S Kanaan","year":"2020","journal-title":"Cephalalgia"},{"issue":"01","key":"ref60","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1186\/s10194-020-01148-9","article-title":"Effect of age on pharmacokinetics, efficacy, and safety of galcanezumab treatment in adult patients with migraine: results from six phase 2 and phase 3 randomized clinical trials","volume":"21","author":"V L Stauffer","year":"2020","journal-title":"J Headache Pain"},{"issue":"01","key":"ref61","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/s10194-021-01227-5","article-title":"Safety and tolerability of eptinezumab in patients with migraine: a pooled analysis of 5 clinical trials","volume":"22","author":"T R Smith","year":"2021","journal-title":"J Headache Pain"},{"issue":"01","key":"ref62","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1186\/s10194-021-01351-2","article-title":"Efficacy and safety of fremanezumab in clinical trial participants aged \u226560\u2009years with episodic or chronic migraine: pooled results from 3 randomized, double-blind, placebo-controlled phase 3 studies","volume":"22","author":"S J Nahas","year":"2021","journal-title":"J Headache Pain"},{"key":"ref63","volume-title":"Aimovig (erenumab-aooe) Prescribing Information","year":"2020"},{"issue":"01","key":"ref64","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1111\/head.14051","article-title":"Hypertension: a new safety risk for patients treated with erenumab","volume":"61","author":"S Saely","year":"2021","journal-title":"Headache"},{"issue":"09","key":"ref65","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1111\/head.14208","article-title":"Risk of hypertension in erenumab-treated patients with migraine: analyses of clinical trial and postmarketing data","volume":"61","author":"D W Dodick","year":"2021","journal-title":"Headache"},{"issue":"13","key":"ref66","doi-asserted-by":"crossref","first-page":"1960","DOI":"10.1177\/0333102418771376","article-title":"A phase 1 study to assess the pharmacokinetics, safety, and tolerability of fremanezumab doses (225\u2009mg, 675\u2009mg and 900\u2009mg) in Japanese and Caucasian healthy subjects","volume":"38","author":"O Cohen-Barak","year":"2018","journal-title":"Cephalalgia"},{"key":"ref67","volume-title":"AJOVY (fremanezumab-vfrm) Injection Current Prescribing Information","year":"2018"},{"key":"ref68","volume-title":"Emgality [Prescribing Information]","year":"2018"},{"issue":"02","key":"ref69","doi-asserted-by":"crossref","first-page":"e00567","DOI":"10.1002\/prp2.567","article-title":"Population pharmacokinetic and exposure-response analysis of eptinezumab in the treatment of episodic and chronic migraine","volume":"8","author":"B Baker","year":"2020","journal-title":"Pharmacol Res Perspect"},{"issue":"10","key":"ref70","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1111\/head.14007","article-title":"Eptinezumab demonstrated efficacy in sustained prevention of episodic and chronic migraine beginning on day 1 after dosing","volume":"60","author":"D W Dodick","year":"2020","journal-title":"Headache"},{"key":"ref71","volume-title":"VYEPTI (eptinezumab-jjmr) [package insert]","year":"2020"},{"issue":"02","key":"ref72","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1007\/s40122-021-00264-x","article-title":"Real-world evidence for control of chronic migraine patients receiving CGRP monoclonal antibody therapy added to OnabotulinumtoxinA: a retrospective chart review","volume":"10","author":"A M Blumenfeld","year":"2021","journal-title":"Pain Ther"},{"key":"ref73","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S0140-6736(20)32544-7","article-title":"Oral rimegepant for preventive treatment of migraine: a phase 2\/3, randomised, double-blind, placebo-controlled trial","volume":"397","author":"R Croop","year":"2021","journal-title":"Lancet"},{"issue":"08","key":"ref74","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1056\/NEJMoa2035908","article-title":"Atogepant for the preventive treatment of migraine","volume":"385","author":"J Ailani","year":"2021","journal-title":"N Engl J Med"},{"key":"ref75","volume-title":"NURTEC ODT","year":"2021"},{"issue":"S 02","key":"ref77","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1111\/head.13586","article-title":"Neuromodulation for the acute and preventive therapy of migraine and cluster headache","volume":"59","author":"R B Halker Singh","year":"2019","journal-title":"Headache"},{"issue":"06","key":"ref79","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1177\/0333102418762525","article-title":"A multicenter, prospective, single arm, open label, observational study of sTMS for migraine prevention (ESPOUSE Study)","volume":"38","author":"A J Starling","year":"2018","journal-title":"Cephalalgia"},{"issue":"05","key":"ref80","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1111\/head.13284","article-title":"Transcranial magnetic stimulation for migraine prevention in adolescents: a pilot open-label study","volume":"58","author":"S L Irwin","year":"2018","journal-title":"Headache"},{"issue":"04","key":"ref82","doi-asserted-by":"crossref","first-page":"e364","DOI":"10.1212\/WNL.0000000000005857","article-title":"Noninvasive vagus nerve stimulation as acute therapy for migraine: the randomized PRESTO study","volume":"91","author":"C Tassorelli","year":"2018","journal-title":"Neurology"},{"issue":"08","key":"ref83","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1212\/WNL.0b013e3182825055","article-title":"Migraine prevention with a supraorbital transcutaneous stimulator: a randomized controlled trial","volume":"80","author":"J Schoenen","year":"2013","journal-title":"Neurology"},{"issue":"02","key":"ref84","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1111\/head.13217","article-title":"Magnesium in migraine prophylaxis - Is there an evidence-based rationale? A systematic review","volume":"58","author":"A von Luckner","year":"2018","journal-title":"Headache"},{"issue":"04","key":"ref85","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.3390\/ijerph18041503","article-title":"Non-pharmacological approaches to headaches: non-invasive neuromodulation, nutraceuticals, and behavioral approaches","volume":"18","author":"L Grazzi","year":"2021","journal-title":"Int J Environ Res Public Health"},{"issue":"09","key":"ref86","doi-asserted-by":"crossref","first-page":"103","DOI":"10.4103\/0973-7847.79105","article-title":"Feverfew (Tanacetum parthenium L.): a systematic review","volume":"5","author":"A Pareek","year":"2011","journal-title":"Pharmacogn Rev"},{"key":"ref87","first-page":"1018","article-title":"Nutraceutical and other modalities for the treatment of headache","volume":"21","author":"S J Tepper","year":"2015","journal-title":"Continuum (Minneap Minn)"},{"issue":"03","key":"ref88","doi-asserted-by":"crossref","first-page":"e14099","DOI":"10.1097\/MD.0000000000014099","article-title":"Therapeutic role of melatonin in migraine prophylaxis: a systematic review","volume":"98","author":"R Long","year":"2019","journal-title":"Medicine (Baltimore)"},{"issue":"04","key":"ref89","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1007\/s10194-011-0329-1","article-title":"Headache and migraine during pregnancy and puerperium: the MIGRA-study","volume":"12","author":"E V Kvisvik","year":"2011","journal-title":"J Headache Pain"},{"issue":"01","key":"ref90","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/head.14041","article-title":"Management of primary headaches during pregnancy, postpartum, and breastfeeding: a systematic review","volume":"61","author":"I J Saldanha","year":"2021","journal-title":"Headache"},{"issue":"10","key":"ref91","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1007\/s11916-021-00980-1","article-title":"The use of behavioral modalities for headache during pregnancy and breastfeeding","volume":"25","author":"N Riggins","year":"2021","journal-title":"Curr Pain Headache Rep"},{"issue":"01","key":"ref92","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1111\/head.13665","article-title":"Epidemiology and treatment of menstrual migraine and migraine during pregnancy and lactation: a narrative review","volume":"60","author":"R Burch","year":"2020","journal-title":"Headache"},{"key":"ref93","volume-title":"Hale's Medications and Mothers' Milk","author":"T W Hale","year":"2021"},{"issue":"01","key":"ref94","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1186\/s10194-020-01196-1","article-title":"OnabotulinumtoxinA for chronic migraine during pregnancy: a real world experience on 45 patients","volume":"21","author":"H T Wong","year":"2020","journal-title":"J Headache Pain"},{"key":"ref95","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1186\/s10194-015-0535-3","article-title":"Single-pulse transcranial magnetic stimulation (sTMS) for the acute treatment of migraine: evaluation of outcome data for the UK post market pilot program","volume":"16","author":"R Bhola","year":"2015","journal-title":"J Headache Pain"},{"issue":"04","key":"ref97","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1007\/s11910-015-0533-5","article-title":"Behavioral treatments for migraine management: useful at each step of migraine care","volume":"15","author":"A B Singer","year":"2015","journal-title":"Curr Neurol Neurosci Rep"},{"issue":"06","key":"ref98","first-page":"CD001218","article-title":"Acupuncture for the prevention of episodic migraine","author":"K Linde","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"issue":"02","key":"ref99","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1111\/head.13723","article-title":"Systematic review: acupuncture vs standard pharmacological therapy for migraine prevention","volume":"60","author":"N Zhang","year":"2020","journal-title":"Headache"},{"issue":"05","key":"ref100","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1111\/j.1526-4610.2007.00789.x","article-title":"Effectiveness of yoga therapy in the treatment of migraine without aura: a randomized controlled trial","volume":"47","author":"P J John","year":"2007","journal-title":"Headache"},{"issue":"01","key":"ref101","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1007\/s11916-012-0304-9","article-title":"Behavioral therapy for chronic migraine","volume":"17","author":"F Pistoia","year":"2013","journal-title":"Curr Pain Headache Rep"}],"container-title":["Seminars in Neurology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/s-0042-1758781.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,14]],"date-time":"2022-12-14T06:32:19Z","timestamp":1670999539000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/s-0042-1758781"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10]]},"references-count":96,"journal-issue":{"issue":"05","published-online":{"date-parts":[[2022,12,13]]},"published-print":{"date-parts":[[2022,10]]}},"URL":"https:\/\/doi.org\/10.1055\/s-0042-1758781","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0271-8235","1098-9021"],"issn-type":[{"value":"0271-8235","type":"print"},{"value":"1098-9021","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10]]}}}